Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elicera Therapeutics ABFRA:8E8 -2.74%25 Forward PE Ratio is 2.34 as of Aug. 18, 2026. GuruFocus rates FRA:8E8 with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 357 Biotechnology companies, Elicera Therapeutics AB ranks better than 89.92% on this metric.
Elicera Therapeutics AB (FRA:8E8) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Elicera Therapeutics AB Forward PE Ratio Related Terms
Elicera Therapeutics AB Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elicera Therapeutics AB Forward PE Ratio Chart
Elicera Therapeutics AB Annual Data
Trend
2025-12
Forward PE Ratio
5.43
Elicera Therapeutics AB Quarterly Data
2025-09
2025-12
2026-03
Forward PE Ratio
4.76
5.43
5.47
FRA:8E8 vs VRTX, REGN, RVMD: Forward PE Ratio Comparison
For the Biotechnology subindustry, Elicera Therapeutics AB's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicera Therapeutics AB Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Elicera Therapeutics AB's Forward PE Ratio falls into.
Elicera Therapeutics AB Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Elicera Therapeutics AB (FRA:8E8) has a Forward PE Ratio of 2.34 as of Aug. 18, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Elicera Therapeutics AB and its competitors. According to the industry distribution chart, Elicera Therapeutics AB ranks #36 out of 357 companies in the Biotechnology industry, placing it in the top 10.1%.
Is Elicera Therapeutics AB's Forward PE Ratio too high?
Elicera Therapeutics AB's current Forward PE Ratio is 2.34. The Biotechnology industry median Forward PE Ratio is 23.00. Elicera Therapeutics AB's value of 2.34 is 89.8% below this industry median. Based on the distribution chart, Elicera Therapeutics AB ranks #36 out of 357 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Elicera Therapeutics AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Elicera Therapeutics AB's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Elicera Therapeutics AB ranks #36 out of 357 companies for Forward PE Ratio. This places Elicera Therapeutics AB in the top 10% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 23.00. Elicera Therapeutics AB's value of 2.34 is 89.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 23.00, based on 357 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elicera Therapeutics AB's current Forward PE Ratio of 2.34 is 89.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Elicera Therapeutics AB and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 23.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elicera Therapeutics AB's current Forward PE Ratio is 2.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicera Therapeutics AB stock overvalued right now?
Elicera Therapeutics AB (FRA:8E8) has a current Forward PE Ratio of 2.34. The current Forward PE Ratio is 2.34 and 89.8% below the Biotechnology industry median of 23.00. Elicera Therapeutics AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Elicera Therapeutics AB (FRA:8E8), the current Forward PE Ratio is 2.34 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
25GF Score
Get the complete analysis for FRA:8E8
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8E8 has been successfully added to your 
